An Open-label, Single-arm, Multicenter, Prospective Study of Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Latest Information Update: 04 Mar 2024
At a glance
- Drugs Lorlatinib (Primary)
- Indications Brain metastases; Meningeal carcinomatosis; Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Mar 2024 New trial record